Previous 10 | Next 10 |
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR A nnual M eeti ng being held April 8-13 in New Orleans, LA LAWRENCEVILLE, N.J., April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Cor...
LAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 1,328,274 shar...
LAWRENCEVILLE, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the company reported a cash position of $56.9 million as of December 31, 2021 during...
Celsion Corporation (CLSN) Q4 2021 Earnings Conference Call March 31, 2022 11:00 A.M. ET Company Participants Monique Kosse - Managing Director, LifeSci Advisors Michael Tardugno - Chairman, President and Chief Executive Officer Jeffrey Church - Senior Vice President, Chief Financial Officer ...
Celsion press release (NASDAQ:CLSN): FY GAAP EPS of -$3.83 beats by $0.22. Revenue of $0.5M in-line (flat Y/Y). For further details see: Celsion GAAP EPS of -$3.83 beats by $0.22, revenue of $0.5M in-line
Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-development ...
ACTG, AFMD, OTCPK:BRPHF, OTCQX:CBWTF, CLSN, GOED, LTRY, NNDM, NNOX, PDSB, PLX, PTR, TRVN, WBA For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open
LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ...
Celsion (CLSN) received $1.4M in net cash proceeds from the sale of ~$1.5M of its unused New Jersey net operating losses. Strengthening its balance sheet, this non-dilutive funding adds to the $55M+ in gross proceeds from equity offerings completed in 2021. Over ...
Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024 Additional $3.5 million of unused state NOLs expected to be sold in future years LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (...
News, Short Squeeze, Breakout and More Instantly...
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage drug development company, today announced ...
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-ba...
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24 th An...